| Anna Mariah Kirsch, MD | |
|
303 Parkway Dr Ne, Atlanta, GA 30312-1212 | |
| (404) 265-4899 | |
| Not Available |
| Full Name | Anna Mariah Kirsch |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 303 Parkway Dr Ne, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467849570 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 80458 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emory University Hospital Midtown | Atlanta, GA | Hospital |
| Emory University Hospital | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Emory Clinic, Inc | 8820901408 | 2687 |
News Archive
Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters - the most common source of these infections - are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
› Verified 7 days ago
| Entity Name | The Emory Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters - the most common source of these infections - are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
› Verified 7 days ago
| Entity Name | Emory Medical Care Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063452381 PECOS PAC ID: 4981501814 Enrollment ID: O20031217000968 |
News Archive
Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters - the most common source of these infections - are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
› Verified 7 days ago
| Entity Name | South Fulton Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821043787 PECOS PAC ID: 5294708715 Enrollment ID: O20040813000595 |
News Archive
Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters - the most common source of these infections - are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
› Verified 7 days ago
| Entity Name | Emory Specialty Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407864168 PECOS PAC ID: 3476559782 Enrollment ID: O20061010000447 |
News Archive
Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters - the most common source of these infections - are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
› Verified 7 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters - the most common source of these infections - are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna Mariah Kirsch, MD 274 8th St Ne, Apt 4, Atlanta, GA 30309-4297 Ph: (850) 443-0470 | Anna Mariah Kirsch, MD 303 Parkway Dr Ne, Atlanta, GA 30312-1212 Ph: (404) 265-4899 |
News Archive
Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
It's a statistic that almost every healthcare facility knows: 40 percent of all healthcare-acquired infections are urinary tract infections (UTI). Since catheters - the most common source of these infections - are used on over four million hospital patients a year, the chances of a patient getting a UTI are pretty high. In fact, the daily risk for patients acquiring a urinary infection is as high as seven percent when indwelling urethral catheters remain in their original position.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
› Verified 7 days ago
Dr. Benjamin Aaron Levy, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5665 New Northside Dr Nw, Suite 200, Atlanta, GA 30328 Phone: 770-874-5400 | |
Essi I Peers, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5665 New Northside Dr Ste 200, Atlanta, GA 30328 Phone: 770-874-5400 | |
Prince N Martin, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5665 Peachtree Dunwoody Rd, Atlanta, GA 30342 Phone: 678-843-7001 | |
Melissa H White, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Jesse Hill Jr Dr Se, Atlanta, GA 30303 Phone: 404-616-4307 Fax: 404-616-8022 | |
John H Lloyd, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1358 Middlesex Ave Ne, Atlanta, GA 30306 Phone: 404-944-7563 | |
Dr. Vida M. Reklaitis, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Johnson Ferry Rd Ne, Atlanta, GA 30342 Phone: 404-851-6936 Fax: 404-851-6024 | |
Dr. Steven M Joyce, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2292 Peachtree Rd., Nw, Atlanta, GA 30309 Phone: 801-558-7791 |